Journal article
Does the Regulatory Environment for E-Cigarettes Influence the Effectiveness of E-Cigarettes for Smoking Cessation?: Longitudinal Findings From the ITC Four Country Survey
Hua-Hie Yong, Sara C Hitchman, K Michael Cummings, Ron Borland, Shannon ML Gravely, Ann McNeill, Geoffrey T Fong
NICOTINE & TOBACCO RESEARCH | OXFORD UNIV PRESS | Published : 2017
DOI: 10.1093/ntr/ntx056
Abstract
Introduction: To date, no studies have explored how different regulatory environments may influence the effectiveness of electronic cigarettes (ECs) as a smoking cessation aid. Objective: This study compares the real-world effectiveness of adult smokers using ECs for quitting compared with quitting unassisted or quitting with nicotine replacement therapy (NRT) and/or prescription medications in two countries with restrictive policies towards ECs (ie, Canada and Australia) versus two countries with less restrictive policies (ie, United States and United Kingdom). Methods: Data were drawn from the International Tobacco Control Four Country surveys, from the United States and Canada (2 waves, n..
View full abstractRelated Projects (1)
Grants
Awarded by US National Cancer Institute
Awarded by Canadian Institutes of Health Research
Awarded by National Health and Medical Research Council of Australia
Awarded by National Institute for Health Research under UK Clinical Research Collaboration
Awarded by Cancer Research UK
Awarded by NATIONAL CANCER INSTITUTE
Funding Acknowledgements
The ITC Four Country Survey during 2010-2014 was supported by multiple grants from the US National Cancer Institute including R01 CA100362, P01 CA138389, and P01 CA138389-06S1. Additional grant support was provided by the Canadian Institutes of Health Research (79551, 115016, and FDN-14877), and National Health and Medical Research Council of Australia (265903, 450110, APP1005922). Work conducted for this article was also partially supported by grants from the US National Cancer Institute (P01 CA200512) and National Health and Medical Research Council of Australia (APP1106451). AM and SCH are members of the UK Centre for Tobacco & Alcohol Studies, a UK Clinical Research Collaboration Public Health Research: Centre of Excellence whose work is supported by funding from the Medical Research Council, British Heart Foundation, Economic and Social Research Council, and the National Institute for Health Research under the auspices of the UK Clinical Research Collaboration (MR/K023195/1). AM and SCH are also funded by Cancer Research UK (C25586/A19540). GTF is supported by a Senior Investigator Award from the Ontario Institute for Cancer Research and a Prevention Scientist Award from the Canadian Cancer Society Research Institute. SMLG is supported by a Canadian Cancer Society Career Development Award in Prevention.